Teva Pharmaceutical Industries Ltd. (TEVA)

17.25
0.15 0.86
NYSE : Health Technology
Prev Close 17.40
Open 17.40
Day Low/High 17.18 / 17.58
52 Wk Low/High 14.59 / 25.96
Volume 8.50M
Avg Volume 10.49M
Exchange NYSE
Shares Outstanding 1.02B
Market Cap 19.59B
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Do we have to run for the hills? Not necessarily.

I See No Technical Reason to Approach Teva Pharmaceuticals From the Long Side

I See No Technical Reason to Approach Teva Pharmaceuticals From the Long Side

Jim Cramer was bearish on TEVA.

Mylan May Make Generics but Its Charts are Starting to Look 'Name Brand'

Mylan May Make Generics but Its Charts are Starting to Look 'Name Brand'

Let's check of the charts and indicators to see if this is a good time to approach the long side of MYL.

Eli Lilly Shares Decline on Tuesday Despite Strong Earnings Release

Eli Lilly Shares Decline on Tuesday Despite Strong Earnings Release

Eli Lilly's excellent earnings weren't excellent enough.

Eli Lilly Offers Healthy Outlook to Kick Off November

Eli Lilly Offers Healthy Outlook to Kick Off November

The giant drugmaker raised its profit guidance for all of 2018 after its third-quarter results beat expectations.

Markets Are Headed For a More Difficult Environment: Market Recon

Markets Are Headed For a More Difficult Environment: Market Recon

Santa is on his way... A lot of pressure on the jolly fellow this year.

Amarin's Huge Rally: Here's Why the Stock Is Soaring and How to Trade It

Amarin's Huge Rally: Here's Why the Stock Is Soaring and How to Trade It

For equity holders in Amarin, now's the time to be implementing my 'Jensen Rules.'

How I See Biotechs Now

How I See Biotechs Now

I expect deal volume to have a substantial uptick before the end of 2018 rolls around.

Retailers Offering Safe Havens

"Despite a voluminous and often fervent literature on "income distribution," the cold fact is that most income is not distributed: It is earned."  -- Thomas Sowell Markets are pretty much trading at the same levels as our last update as it looks lik...

Five-Day Winning Streak in Stocks Expected to Continue

Five-Day Winning Streak in Stocks Expected to Continue

On Thursday alone, we experience both free-fall, as well as a raucous rally.

Jim Cramer: The SEC Should Admit It Goofed With These Crazy Instruments

Jim Cramer: The SEC Should Admit It Goofed With These Crazy Instruments

We used to think of what's in the public's interest when it comes to securities.

Clearly, Warren Buffett Loves Apple's Stock

Clearly, Warren Buffett Loves Apple's Stock

Warren Buffett continues to eat up Apple's stock. He also has bought a stake in struggling generics drug maker Teva.

What's Behind the Hound of Hades' Stock Market Rampage

What's Behind the Hound of Hades' Stock Market Rampage

The free market is going to take back control of interest rates.

This Is the Best Advice We Can Give After the Dow Jones Industrial Average Crash

This Is the Best Advice We Can Give After the Dow Jones Industrial Average Crash

The stock market continues to be under considerable pressure. Here is one thing not to do right now amidst the carnage.

Are Politics and Proxy Firms Killing Your Investment Returns?

Are Politics and Proxy Firms Killing Your Investment Returns?

Gains are being left on the table as firms and investors let their politics or social concerns get the better of them.

Generic-Drug Stocks Are Looking Sickly

I'm seeing some weakness in generic-drug stocks -- i.e., Teva Pharmaceuticals , Mylan and Mallinckrodt -- based on a New York Times article that hospitals might move into the generic-drug business.

Try This Pair of Biotech Trades

Try This Pair of Biotech Trades

Teva and Mallinckrodt both lost over 50% of their value in 2017 and might catch some momentum here.

Dow Jumps to New Intraday High as Deal News Boosts Wall Street

Dow Jumps to New Intraday High as Deal News Boosts Wall Street

Stocks were slightly higher.

Wrap Up

I was out of the office most of the day. To me the most interesting asset class move was in bonds -- with yields down by over five basis points. The 10-year yield fell to under 2.35% though the 2s/10s curve was flat. While municipals rallied in pric...

SNF Wins The Night But Loses Viewers: LIVE MARKETS BLOG

SNF Wins The Night But Loses Viewers: LIVE MARKETS BLOG

The broadcast scored an 11.6 metered rating, tops on the night, but short of last week's total.

Staying Liquid

I missed very little and was better served at my "liquid" lunch meeting. Bitcoin was being bitcoin (+17%) with prices contrasting wildly by Exchanges -- a signpost that volatility will be with this commodity for some time. I have a double dose of Bo...

Mid-Afternoon Observations

Some mid afternoon observations:   * Small yield flattening in today's session and little change in bond yields. * High yield is slipping a bit. * The U.S. Dollar is strengthening after morning weakness. * Oil down after weeks of strength (-$0.76/ba...

Markets Close 'Green' on Black Friday

Markets Close 'Green' on Black Friday

While shoppers were busy looking for bargains at the mall, traders were busy doing the same on Wall Street.

Wells Fargo Labels Teva in 'Survival Mode'

This morning Wells Fargo research describes Teva Pharmaceutical Industries as being "in survival mode."   The brokerage expects a 20% reduction in employment (this is broadly anticipated).    The company reported in Israel that Teva currently doesn'...

Why Teva Will Be Hard Pressed to Maintain Its Dividend in the Long Term

Why Teva Will Be Hard Pressed to Maintain Its Dividend in the Long Term

The troubled drug firm slashed its dividend by 75% in August, but its current dividend payout ratio and yield can tell us a lot about the future.

Biotech Stocks to Watch: Part 1

Biotech Stocks to Watch: Part 1

Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.

Here's What's Up This A.M.

The Nasdaq (QQQs) turn slightly negative as most of the FANGs reverse lower.   Retail, generics (Teva and Mylan ), big pharma (Merck and Bristol-Myers Squibb ) and biotech (Allergan , Gilead Sciences , Celgene ) are conspicuous to the downside.   Co...